Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pyxis OncologyPYXS -7.99%22 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates PYXS with a GF Score™ of 22/100. The stock has 5 warning signs investors should review. Among 941 Biotechnology companies, Pyxis Oncology ranks worse than 73.33% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Pyxis Oncology's EBITDA for the
three
months ended in Mar. 2026 was $-23.90 Mil. Pyxis Oncology's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Pyxis Oncology's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Pyxis Oncology EBITDA Margin % Related Terms
Pyxis Oncology EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Pyxis Oncology's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PYXS vs ORMP, CAMP, ALEC: EBITDA Margin % Comparison
For the Biotechnology subindustry, Pyxis Oncology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pyxis Oncology EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pyxis Oncology's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Pyxis Oncology's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pyxis Oncology (PYXS) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pyxis Oncology and its competitors. According to the industry distribution chart, Pyxis Oncology ranks #690 out of 941 companies in the Biotechnology industry, placing it in the top 73.3%.
Is Pyxis Oncology's EBITDA Margin % too high?
Pyxis Oncology's current EBITDA Margin % is 0.00%. Based on the distribution chart, Pyxis Oncology ranks #690 out of 941 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pyxis Oncology has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Pyxis Oncology's EBITDA Margin % compare to ORMP and CAMP?
According to the Biotechnology industry distribution chart, Pyxis Oncology ranks #690 out of 941 companies for EBITDA Margin %. This places Pyxis Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pyxis Oncology and its competitors. Pyxis Oncology's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pyxis Oncology stock overvalued right now?
Pyxis Oncology (PYXS) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Pyxis Oncology's overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Pyxis Oncology (PYXS), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
22GF Score
Get the complete analysis for PYXS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PYXS has been successfully added to your 
